ALLOHIGH SIGNALRISK10-K

ALLO disclosed a Grade 5 serious adverse event (death) in their ALPHA3 trial that forced discontinuation of a treatment arm, while burning through cash at an alarming rate with only $51.7M remaining.

The addition of explicit language about a Grade 5 SAE (patient death) and regulatory risks represents a material safety setback that could derail their lead program and expose the company to significant liability. With cash declining 31% to just $51.7M and continued massive operating losses, ALLO faces an urgent funding crisis that threatens their ability to complete critical trials expected to read out in Q2 2026.

Comparing 2026-03-12 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

Despite reducing R&D spending by 22% to $150.2M, ALLO's financial position deteriorated significantly with cash declining 31% to $51.7M, stockholders' equity falling 31% to $292.5M, and total assets shrinking 24%. While operating losses improved 23% to -$209.3M due to cost cutting measures, the company is burning approximately $149M annually in operating cash flow, leaving them with less than 5 months of runway at current spending levels. The reduced capital expenditures and manufacturing operations signal potential constraints on their development capabilities during this critical period.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-44.4%
$694K$386K

Capex reduced 44.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-31.3%
$75.2M$51.7M

Cash declined 31.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-30.7%
$422.2M$292.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
+25.9%
-$257.6M-$190.9M

Net income grew 25.9% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+25.5%
-$200.3M-$149.2M

Operating cash flow grew 25.5% — strong conversion of earnings to cash, healthy business fundamentals.

Total Assets
Balance Sheet
-24.2%
$548.7M$415.9M

Total assets contracted 24.2% — asset sales, write-downs, or balance sheet optimization underway.

Operating Income
P&L
+23.4%
-$273.2M-$209.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

R&D Expense
P&L
-21.9%
$192.3M$150.2M

R&D spending cut 21.9% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-15%
$303.4M$257.7M

Current assets declined 15% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-13
ADDED
Risks related to serious adverse events (SAEs) in the discontinued fludarabine, cyclophosphamide, and ALLO-647 (FCA) arm of our ALPHA3 trial, including the Grade 5 SAE, could lead to regulatory actions, negative perceptions, and potential product liability claims.
Reduced manufacturing operations may limit our ability to timely support our development programs.
Disruptions to the operations of the FDA, the SEC and other government agencies, including comparable foreign regulatory authorities, resulting from funding shortages, policy initiatives, staffing reductions or related uncertainty, could impair their ability to perform regulatory functions and negatively impact our business.
There is uncertainty regarding whether the use of fludarabine and cyclophosphamide (FC) without ALLO-647 will achieve sufficient lymphodepletion to support the efficacy of our allogeneic CAR T product candidate in the ALPHA3 trial.
We are heavily reliant on our partners, Cellectis and Servier, for access to TALEN gene editing technology for the manufacturing and development of our oncology product candidates.
+7 more — sign up free →
REMOVED
Changes in funding for the FDA, the SEC and other government agencies including comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
Risks Related to the Development of Our Product Candidates Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment and treatment of autoimmune diseases, which creates significant challenges for us.
Last year we executed our 2024 Platform Vision, which we believe will redefine the future of chimeric antigen receptor (CAR) T therapy by leveraging the unique attributes of allogeneic CAR T products.
Renal Cell Carcinoma (RCC) : TRAVERSE trial with ALLO-316 seeks to advance scientific innovation underlying the Dagger technology to optimize CAR T cell expansion and persistence, thereby maximizing the potential of allogeneic CAR T in solid tumors while mitigating treatment-associated inflammatory response.
Although we are currently focusing on our three core development programs noted above, we continue to have a deep pipeline to further the research and development of allogeneic CAR T cell product candidates in both hematological malignancies and solid tumors.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →